ProCE Banner Activity

TRANSCEND FL: Lisocabtagene Maraleucel as Second-Line Therapy for Patients With High-Risk R/R Follicular Lymphoma

Conference Coverage

In a primary analysis of the second-line treatment cohort of the TRANSCEND FL phase II trial, lisocabtagene maraleucel was associated with very high ORR and CR rates, as well as manageable safety, for patients with relapsed or refractory high-risk follicular lymphoma.

Released: December 13, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.